{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fibrillines : Questions médicales les plus fréquentes",
"headline": "Fibrillines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fibrillines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-24",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fibrillines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de la matrice extracellulaire",
"url": "https://questionsmedicales.fr/mesh/D016326",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de la matrice extracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D016326",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Fibrilline-1",
"alternateName": "Fibrillin-1",
"url": "https://questionsmedicales.fr/mesh/D000071838",
"about": {
"@type": "MedicalCondition",
"name": "Fibrilline-1",
"code": {
"@type": "MedicalCode",
"code": "D000071838",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300.400.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fibrilline-2",
"alternateName": "Fibrillin-2",
"url": "https://questionsmedicales.fr/mesh/D000071840",
"about": {
"@type": "MedicalCondition",
"name": "Fibrilline-2",
"code": {
"@type": "MedicalCode",
"code": "D000071840",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300.400.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Fibrillines",
"alternateName": "Fibrillins",
"code": {
"@type": "MedicalCode",
"code": "D000071837",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Dieter P Reinhardt",
"url": "https://questionsmedicales.fr/author/Dieter%20P%20Reinhardt",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada. dieter.reinhardt@mcgill.ca."
}
},
{
"@type": "Person",
"name": "Clair Baldock",
"url": "https://questionsmedicales.fr/author/Clair%20Baldock",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, The University of Manchester, Manchester, UK."
}
},
{
"@type": "Person",
"name": "Gerhard Sengle",
"url": "https://questionsmedicales.fr/author/Gerhard%20Sengle",
"affiliation": {
"@type": "Organization",
"name": "Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Cologne Center for Musculoskeletal Biomechanics (CCMB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany."
}
},
{
"@type": "Person",
"name": "Stuart A Cain",
"url": "https://questionsmedicales.fr/author/Stuart%20A%20Cain",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom."
}
},
{
"@type": "Person",
"name": "Muthu L Muthu",
"url": "https://questionsmedicales.fr/author/Muthu%20L%20Muthu",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Systems analysis and improvement approach to improve naloxone distribution within syringe service programs: study protocol of a randomized controlled trial.",
"datePublished": "2023-08-03",
"url": "https://questionsmedicales.fr/article/37537665",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13012-023-01288-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Redefining the health system: A proposed updated framework of a systems approach to health.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/36045732",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2022.956487"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing the sustainability of the Systems Analysis and Improvement Approach to increase HIV testing in family planning clinics in Mombasa, Kenya: results of a cluster randomized trial.",
"datePublished": "2022-10-04",
"url": "https://questionsmedicales.fr/article/36195890",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13012-022-01242-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systems analysis and improvement approach to optimize outpatient mental health treatment cascades in Mozambique (SAIA-MH): study protocol for a cluster randomized trial.",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35668423",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13012-022-01213-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing the design of road traffic death information systems in Iran: A participatory systems approach.",
"datePublished": "2023-01-26",
"url": "https://questionsmedicales.fr/article/36787688",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijmedinf.2023.105005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Scléroprotéines",
"item": "https://questionsmedicales.fr/mesh/D012596"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de la matrice extracellulaire",
"item": "https://questionsmedicales.fr/mesh/D016326"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fibrillines",
"item": "https://questionsmedicales.fr/mesh/D000071837"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fibrillines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fibrillines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fibrillines",
"description": "Comment diagnostiquer une déficience en fibrilline ?\nQuels examens sont utilisés pour évaluer les fibrillines ?\nLes tests génétiques sont-ils fiables pour les fibrillines ?\nQuels symptômes indiquent un problème de fibrilline ?\nPeut-on détecter des anomalies fibrillaires par imagerie ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fibrillines",
"description": "Quels sont les symptômes d'une maladie liée aux fibrillines ?\nLes douleurs articulaires sont-elles liées aux fibrillines ?\nY a-t-il des signes cutanés associés aux fibrillines ?\nLes problèmes oculaires sont-ils fréquents avec les fibrillines ?\nComment les anomalies cardiovasculaires se manifestent-elles ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fibrillines",
"description": "Peut-on prévenir les maladies liées aux fibrillines ?\nY a-t-il des conseils de mode de vie pour les patients fibrillaires ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nComment le suivi médical aide-t-il les patients ?\nLes activités physiques sont-elles sûres pour les patients ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fibrillines",
"description": "Quels traitements existent pour les troubles des fibrillines ?\nLa chirurgie est-elle nécessaire pour les problèmes de fibrillines ?\nDes médicaments peuvent-ils aider les patients fibrillaires ?\nY a-t-il des thérapies spécifiques pour les fibrillines ?\nComment gérer les douleurs liées aux fibrillines ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fibrillines",
"description": "Quelles sont les complications possibles des troubles fibrillaires ?\nLes complications cardiovasculaires sont-elles fréquentes ?\nComment prévenir les complications liées aux fibrillines ?\nLes douleurs chroniques sont-elles une complication courante ?\nLes problèmes respiratoires peuvent-ils être liés aux fibrillines ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fibrillines",
"description": "Quels sont les facteurs de risque pour les troubles des fibrillines ?\nLes antécédents familiaux augmentent-ils le risque ?\nLes mutations génétiques sont-elles un facteur de risque ?\nLes conditions médicales préexistantes influencent-elles le risque ?\nL'âge est-il un facteur de risque pour les troubles fibrillaires ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Systems+Analysis&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en fibrilline ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests génétiques et des examens cliniques."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les fibrillines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie, l'IRM et les tests sanguins peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils fiables pour les fibrillines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques sont très fiables pour identifier les mutations des fibrillines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de fibrilline ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs articulaires et des anomalies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies fibrillaires par imagerie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'imagerie peut révéler des anomalies dans les tissus conjonctifs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une maladie liée aux fibrillines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, des problèmes cardiaques et des anomalies oculaires."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires sont-elles liées aux fibrillines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires peuvent être un signe de dysfonctionnement des fibrillines."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés aux fibrillines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cutanés comme des vergetures peuvent être observés en cas de déficience en fibrilline."
}
},
{
"@type": "Question",
"name": "Les problèmes oculaires sont-ils fréquents avec les fibrillines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes comme le décollement de la rétine peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les anomalies cardiovasculaires se manifestent-elles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent se manifester par des dilatations aortiques ou des ruptures vasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux fibrillines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter les problèmes tôt."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils de mode de vie pour les patients fibrillaires ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il les patients ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le suivi médical permet de surveiller l'évolution de la maladie et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres pour les patients ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des activités physiques modérées sont généralement sûres, mais doivent être adaptées à chaque patient."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles des fibrillines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la surveillance, la chirurgie et des médicaments pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle nécessaire pour les problèmes de fibrillines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être nécessaire pour corriger des anomalies cardiovasculaires graves."
}
},
{
"@type": "Question",
"name": "Des médicaments peuvent-ils aider les patients fibrillaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent aider à gérer les symptômes et à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies spécifiques pour les fibrillines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de thérapie spécifique, mais des soins symptomatiques sont offerts."
}
},
{
"@type": "Question",
"name": "Comment gérer les douleurs liées aux fibrillines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de la douleur peut inclure des analgésiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des troubles fibrillaires ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des ruptures vasculaires, des problèmes cardiaques et des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications cardiovasculaires sont courantes et peuvent être graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux fibrillines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et un traitement approprié peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les douleurs chroniques sont-elles une complication courante ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir et nécessitent une gestion adéquate."
}
},
{
"@type": "Question",
"name": "Les problèmes respiratoires peuvent-ils être liés aux fibrillines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes respiratoires peuvent survenir en raison de complications pulmonaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des fibrillines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des conditions médicales."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de troubles fibrillaires augmente le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations génétiques sont directement liées aux troubles des fibrillines."
}
},
{
"@type": "Question",
"name": "Les conditions médicales préexistantes influencent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme le syndrome de Marfan augmentent le risque de complications."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles fibrillaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer la gravité des symptômes, mais n'est pas un facteur de risque direct."
}
}
]
}
]
}
More than half a million Americans died of an opioid-related overdose between 1999 and 2020, the majority occurring between 2015 and 2020. The opioid overdose mortality epidemic disproportionately imp...
We will conduct a trial with 32 SSPs across California, randomly assigning 16 to the SAIA-Naloxone arm and 16 to receive implementation as usual. SAIA-Naloxone is a multifaceted, multilevel implementa...
This trial takes a novel approach to improving equitable distribution of naloxone amid the ongoing epidemic and associated racial disparities. If successful, SAIA-Naloxone represents an important orga...
Defining the health system, as a multidimensional and complex structure, is challenging, and the existing definitions often fail to incorporate the various levels and functions involved in a single sy...
In Kenya, HIV incidence is highest among reproductive-age women. A key HIV mitigation strategy is the integration of HIV testing and counseling (HTC) into family planning services, but successful inte...
Twenty-four family planning clinics in Mombasa County were randomized to either the SAIA implementation strategy or standard care. In Stage 1, the study staff conducted all study activities. In Stage ...
Only 39% (56/144) of planned SAIA visits were completed, largely due to the COVID-19 pandemic and a prolonged healthcare worker strike. In the final study quarter, 81.6% (160/196) of new clients at in...
Intervention clinics demonstrated sustained improvement in HTC after SAIA was transitioned to DOHS leadership despite wide-scale healthcare disruptions and incomplete delivery of the implementation st...
ClinicalTrials.gov (NCT02994355) registered on 16 December 2016....
Significant investments are being made to close the mental health (MH) treatment gap, which often exceeds 90% in many low- and middle-income countries (LMICs). However, limited attention has been paid...
Using a cluster-randomized trial design, 16 clinics (8 intervention and 8 control) providing primary MH care will be randomized to the Systems Analysis and Improvement Approach for Mental Health (SAIA...
This study is innovative in being the first, to our knowledge, to test a multicomponent implementation strategy for MH care cascade optimization in LMICs. By design, SAIA-MH is a low-cost strategy to ...
ClinicalTrials.gov; NCT05103033 ; 11/2/2021....
To describe and analyze the information architecture and information pathways of the road traffic death recording, registration and reporting system in Guilan Province, northernIran....
We used Business Process Mapping, a qualitative approach. This participatory and iterative approach consists of a document review, key informant interviews, development of a process map and a particip...
We identified 13 stakeholders, with operating and influencing roles in the process of identification, registration and production of statistics about road traffic deaths in Guilan province. The three ...
Designing a comprehensive road traffic information system that provides accurate and timely information requires an understanding of the information flow and the entangled web of different stakeholder...
Opioid overdose fatalities are preventable with timely administration of naloxone, an opioid antagonist, during an opioid overdose event. Syringe service programs have pioneered naloxone distribution ...
Two syringe service programs participated in a 6-month pilot of SAIA-Naloxone, which included (1) analyzing program data to identify gaps in the naloxone delivery cascade, (2) flow mapping to identify...
Over the course of the study, 11,107 doses of naloxone were distributed to 6,071 participants. Through SAIA-Naloxone, syringe service programs prioritized testing programmatic modifications to improve...
SAIA-Naloxone has strong potential for improving naloxone distribution from syringe service programs. These findings are encouraging in the face of the worsening opioid overdose crisis in the United S...
Although HIV testing in family planning (FP) clinics is a promising approach for engaging women in HIV treatment and prevention services, HIV testing rates are low in FP clinics in Kenya. In 2018, a c...
We conducted a costing evaluation from the payer perspective for the FP HIV SAIA randomized control trial. We identified relevant activities for the intervention including start-up, training, research...
For an annual program output of 36,086 HIV tests administered to new FP clients, we estimated the total annual program cost to be $91,994 with an average cost per new FP client served of $2.55. Person...
FP HIV SAIA is a low-cost and flexible implementation strategy for facilitating integrated delivery of HIV testing alongside FP services. Although cost implications of the FP HIV SAIA intervention mus...
The trial was registered on December 15, 2016, with clinicaltrials.gov (NCT02994355)....
Recent case studies indicate that the 2014-2016 Ebola outbreak, one of the worst pre-2020 global biological catastrophes in modern history, helped some nations to better prepared their responses for t...
Applying the policy legacies analytical framework and a systematized literature review, this research examines how prior policy experiences with the 2014-16 EVD crisis as a large-scale emergent outbre...
A systematized literature review of 803 evaluated sources assesses to what extent Ebola-affected and non-affected nations directly modified governmental health systems in relation to this warning. The...
Ten (90.9%) of 11 nations that were affected by 2014-16 Ebola crisis have documented evidence of repurposing their EVD-related policies to fight COVID-19. 164 (70.0%) of 234 non-EVD-affected nations h...
The shock of 2014-16 EVD outbreak affected most nations around the world, whether they experienced Ebola cases. We further develop a categorical framework that helps characterised nations previous exp...
Cervical cancer is the leading cause of cancer death in Kenyan women. Integrating cervical cancer screening into family planning (FP) clinics is a promising strategy to improve health for reproductive...
Twenty FP clinics in Mombasa County were randomized 1:1 to SAIA versus usual procedures. SAIA has five steps: (1) cascade analysis tool to understand the cascade and identify inefficiencies, (2) seque...
In the primary intent-to-treat analysis in the last quarter of the trial, 2.5% (37/1507) of visits with eligible FP clients at intervention facilities included cervical cancer screening compared to 3....
The primary analysis did not show an effect on cervical cancer screening. However, the COVID-19 pandemic and a healthcare worker strike likely impacted SAIA's implementation with significant disruptio...
ClinicalTrials.gov, NCT03514459. Registered on April 19, 2018....
The use of point of care (POC) tests varies across Europe, but research into what drives this variability is lacking. Focusing on CRP POC tests, we aimed to understand what factors contribute to high ...
We used a comparative qualitative case study approach to explore the implementation of CRP POC tests in the Netherlands and England. These countries were selected because although they have similar pr...
Sixty-five documents were reviewed and 21 interviews were conducted. The difference in the availability of CRP POC tests is mainly because of differences at the wider national context level. In the tw...
The engagement of early adopters combined with a more favourable and receptive macro level environment, including the role of clinical guidelines and their developers in determining which intervention...